First Tracks Biotherapeutics, Inc. (TRAX)
| Market Cap | 678.99M |
| Revenue (ttm) | n/a |
| Net Income | -166.09M |
| EPS | n/a |
| Shares Out | 34.75M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 355,109 |
| Open | 18.12 |
| Previous Close | 17.82 |
| Day's Range | 17.50 - 19.82 |
| 52-Week Range | 14.79 - 26.80 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 41.00 (+109.83%) |
| Earnings Date | Jun 1, 2026 |
About TRAX
First Tracks Biotherapeutics, Inc. operates as a clinical-stage biotechnology company developing antibody therapeutics that modulate immune pathways implicated in autoimmune and inflammatory diseases. First Tracks Biotherapeutics, Inc. was formerly known as Biopharma Co., Inc. and changed its name to First Tracks Biotherapeutics, Inc. in February 2026. First Tracks Biotherapeutics, Inc. was incorporated in 2025 and is headquartered in San Diego, California. First Tracks Biotherapeutics, Inc. operates as a subsidiary of AnaptysBio, Inc.
Financial Performance
Financial StatementsAnalyst Summary
According to 6 analysts, the average rating for TRAX stock is "Strong Buy." The 12-month stock price target is $41.0, which is an increase of 109.83% from the latest price.
News
First Tracks Biotherapeutics files to sell 10.5M shares of common for holders
16:38 EDT First Tracks Biotherapeutics (TRAX) files to sell 10.5M shares of common for holders
First Tracks Biotherapeutics initiated with an Overweight at Piper Sandler
Piper Sandler analyst Yasmeen Rahimi initiated coverage of First Tracks Biotherapeutics (TRAX) with an Overweight rating and $54 price target The company has a “differentiated pipeline” across ANB033,...
First Tracks Biotherapeutics initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Emily Bodnar initiated coverage of First Tracks Biotherapeutics (TRAX) with a Buy rating and $30 price target The company has a pipeline of clinical-stage immune cell modulatin...
First Tracks Biotherapeutics initiated with an Outperform at Leerink
Leerink analyst David Risinger initiated coverage of First Tracks Biotherapeutics (TRAX) with an Outperform rating and $46 price target. This is an event story, with multiple near-term catalysts, the ...
First Tracks Biotherapeutics initiated with an Overweight at Barclays
Barclays initiated coverage of First Tracks Biotherapeutics (TRAX) with an Overweight rating and $40 price target The firm views the company’s ANB033 as an “anchor asset with significant upside potent...
First Tracks Biotherapeutics initiated with an Overweight at JPMorgan
JPMorgan analyst Anupam Rama initiated coverage of First Tracks Biotherapeutics (TRAX) with an Overweight rating and $31 price target The firm views First Tracks as an emerging clinical stage immunolo...
First Tracks Biotherapeutics Debuts on Nasdaq to Advance Therapies for Autoimmune Diseases
First Tracks Biotherapeutics launches with $180 million in cash and two-year cash-runway Trading of TRAX begins on Nasdaq today SAN DIEGO, April 20, 2026 (GLOBE NEWSWIRE) -- First Tracks Biotherapeuti...